ReviewNature methods2021
Spatial omics and multiplexed imaging to explore cancer biology.
Review in Nature methods, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 356 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
356 citing papers in PubMed, 4 syntheses or guidelines pooled it, 586 citations in OpenAlex.
- Epstein-Barr virus-driven immunosuppression in nasopharyngeal carcinoma: a comprehensive review of viral mechanisms, spatial tumor ecosystems, and precision therapeutics.Frontiers in immunology · 2026Pooled it
- Multilevel Mechanisms of Cancer Drug Resistance.International journal of molecular sciences · 2024Pooled it
- A systematic review of spatial and temporal epidemiological approaches, focus on lung cancer risk associated with particulate matter.BMC public health · 2024Pooled it
- Metabolomic profiling of upper GI malignancies in blood and tissue: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2024Pooled it
- Spatiotemporal dynamics of the host-tumor metabolic interface: Implications for precision nutritional oncology.Genes & diseases · 2026Review
- A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture.Cancer discovery · 2026Article
- Clinical metastatic cancer from initiation to colonization: emerging challenges and breakthroughs.Oncogene · 2026Review
- The spatial architecture of tumor immunity: Emerging predictive biomarkers across cancer.Immunologic research · 2026Review
- Deep Learning-Assisted Prioritization of Candidate Drug Targets in Tumors Using Spatial Multi-Omics.Biology · 2026Review
- Super-resolution imaging using fluorescence-lifetime emission-difference.Biomedical optics express · 2026Article
- Why early pathology input matters in biologically rich cancer trials.British journal of cancer · 2026Review
- Spatial Immune Coding in Tumor-Draining Lymph Nodes: Functional Compartmentalization of Immune Activation and Immunosuppression.International journal of molecular sciences · 2026Review
- Spatially resolved tissue architecture and computational pathology in pancreatic cancer.Experimental & molecular medicine · 2026Review
- Closing the Translational Gap: Closed-Loop AI Discovery Frameworks for Experimental Validation and Clinical Implementation in Cancer Therapeutics.Cancer medicine · 2026Review
- Beyond TLS Presence: A Functional Framework Integrating Maturity, Location, and Immune Context.Cancers · 2026Review
- Spatial Omics Technologies in Glioblastoma Research: Principles, Applications, and Best Practices.Genes · 2026Review
- Integrative spatial multi-omics reveals the tumor ecosystem: From mechanistic insights to therapeutic strategies.iScience · 2026Review
- CD86 in Dendritic Cell-Mediated Cancer Immunity: From Maturation Marker to Functional Regulator.Biomedicines · 2026Review
- Review
- Multimodal spatial omics: From data acquisition to computational integration.Patterns (New York, N.Y.) · 2026Review
296 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding intratumoral heterogeneity-the molecular variation among cells within a tumor-promises to address outstanding questions in cancer biology and improve the diagnosis and treatment of specific cancer subtypes. Single-cell analyses, especially RNA sequencing and other genomics modalities, have been transformative in revealing novel biomarkers and molecular regulators associated with tumor growth, metastasis and drug resistance. However, these approaches fail to provide a complete picture of tumor biology, as information on cellular location within the tumor microenvironment is lost. New technologies leveraging multiplexed fluorescence, DNA, RNA and isotope labeling enable the detection of tens to thousands of cancer subclones or molecular biomarkers within their native spatial context. The expeditious growth in these techniques, along with methods for multiomics data integration, promises to yield a more comprehensive understanding of cell-to-cell variation within and between individual tumors. Here we provide the current state and future perspectives on the spatial technologies expected to drive the next generation of research and diagnostic and therapeutic strategies for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.